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Abstract: The poxvirus vaccinia virus (VV) served as the model virus for which the first 
antivirals, the thiosemicarbazones, were identified. This dates back to 1950; and, although 
there is at present no single antiviral drug specifically licensed for the chemotherapy or  
-prophylaxis of poxvirus infections, numerous candidate compounds have been described 
over the past 50 years. These compounds include interferon and inducers thereof  
(i.e., polyacrylic acid), 5-substituted 2’-deoxyuridines (i.e., idoxuridine), IMP 
dehydrogenase inhibitors, S-adenosylhomocysteine hydrolase inhibitors, acyclic nucleoside 
phosphonates (such as cidofovir) and alkoxyalkyl prodrugs thereof (such as CMX001), viral 
egress inhibitors (such as tecovirimat), and cellular kinase inhibitors (such as imatinib). 
Keywords: thiosemicarbazones; interferon (inducers); idoxuridine (IDU); acyclic 
nucleoside phosphonates; cidofovir; CMX001 (HDP-CDV); tecovirimat (ST-246);  
Gleevec (imatinib) 
 
1. Introduction: The thiosemicarbazones 
In 1972, D.J. Bauer stated in his “Introduction to Antiviral Chemotherapy” [1] that the first true 
antiviral agents discovered were the thiosemicarbazones. They were introduced into medicine by 
Domagk et al. [2], as active against tubercle bacilli. As stated by Bauer [1], “the discovery of an agent 
effective in one branch of microbiological science is usually followed by its trial in other branches”, 
and so, p-aminobenzaldehyde thiosemicarbazone was the first antiviral agent, found in 1950 by 
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Hamre, Bernstein and Donovick [3] to be active against vaccinia virus (VV) infection in fertile eggs 
and mice. This observation was confirmed by Hamre, Brownlee and Donovick in 1951 [4]. Thompson, 
Price and Minton [5] then showed that benzaldehyde thiosemicarbazone protected mice infected 
intracerebrally with VV. 
An example of virus plaque inhibition (in HeLa cells), a technique as originally applied in these 
early days [1], illustrates the central disc containing a compound having activity against rabbit 
poxvirus (Figure 1). The compound has diffused through the agar overlay, and the disc is surrounded 
by a zone where the formation of plaques is inhibited. Which compound inhibited rabbit poxvirus 
plaque formation is not clear from the context.  
Figure 1. Plaque-inhibition test. The central disc contains a compound having activity 
against rabbitpox virus. The compound has diffused through the agar overlay and the disc 
is surrounded by a zone in which the formation of plaques has been inhibited. Figure taken 
from Bauer [1]. 
 
 
In his paper on “Thiosemicarbazones” [6], Bauer contended that the benzaldehyde 
thiosemicarbazones were the first true antiviral agents to be discovered and that “they could have 
yielded antiviral agents useful in human medicine if their development had not come to a halt”. 
Thompson et al. [7] then described a wide range of thiosemicarbazones, from which emerged isatin  
3-thiosemicarbazone [8]. This compound was further studied by Bauer [9] and found to be effective 
against the multiplication of VV in mice infected intracerebrally. The thiosemicarbazone finally 
selected for use in man was 1-methylisatin 3-thiosemicarbazone, better known as methisazone (brand 
name: Marboran). For the structural formulae of the compounds, see the Appendix accompanying this 
article. As further documented by Bauer [1], methisazone had tentative efficacy in the treatment and 
prophylaxis of smallpox, and the treatment of the complications of smallpox vaccination, i.e., eczema 
vaccinatum and vaccinia gangrenosa. Methisazone would have yielded better results than antivaccinial 
-globulin in the prophylaxis of smallpox in persons who had been in contact with variola virus [10]. 
However, with the imminent global eradication of the variola virus (resulting from the successful 
implementation of the smallpox vaccination), interest in the use of methisazone for both the 
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prophylaxis or treatment of smallpox rapidly declined, and so did the interest in further developing 
antiviral compounds active against either variola or vaccinia virus. 
2. The VV pox tail lesion model: the simplest virus mouse model ever described 
Vaccinia virus (VV) was the first virus I worked with when joining the Laboratory of my master, 
Prof. P. De Somer in 1964, as a student in medicine, to work on interferon and inducers thereof. 
Vaccinia virus was at that time not the highest priority as a target virus for antiviral development, but it 
was a useful tool virus for titrating interferon, not dangerous as we were all vaccinated with the virus, 
and extremely stable and reliable as a challenge virus, i.e., for interferon titrations in murine L929 
cells, which at that time I did almost weekly. Then I found VV to be a most useful virus to demonstrate 
the efficacy of interferon and interferon inducers [such as polyacrylic acid (PAA)], even if the latter 
was administered four weeks before VV infection (Table 1) [11]. The model was simple and reliable: 
at 7-10 days after intravenous injection with VV, the mice developed tail lesions which could be easily 
counted, and the reduction in the tail lesion number could be interpreted as a quantitative measure of 
the antiviral activity of any given anti-VV agent. The model was first described by Boyle, Haff and 
Stewart [12], but I found it extremely useful, convenient and accurate to demonstrate in vivo anti-VV 
activity of interferon and interferon inducers [11], and of many nucleoside analogs as well, including 
ribavirin, and 5-substituted 2’-deoxyuridines [13], carbocyclic 3-deazaadenosine [14],  
3’-fluoro-3’-deoxyadenosine [15], (S)-HPMPA [16], EICAR [17], and S2242 [18]. The VV pox tail 
lesion model has also been used by others [19-21] to demonstrate the anti-VV activity of a variety of 
compounds (as reviewed by Smee and Sidwell [22]), but, despite (and probably because of) its 
simplicity, the VV pox tail lesion model has since the review article of Smee and Sidwell [22] in 2003 
no longer popped up in recent publications. 
Table 1. Effect of time of a single polyacrylic acid (PAA) dose on the formation of 
vaccinia virus tail lesions. Data taken from De Clercq and De Somer [11]. 
PAA treatment
a
 
before vaccinia 
virus infection
b 
No. of lesions Probability (comparison 
with control group) 
 Per individual mouse Average  
Control 9, 3, 8, 1, 6, 2, 5, 11, 4, 0, 3, 2, 0, 11, 15, 
10, 30, 4 
6.89  
4 weeks before 0, 1, 0, 5, 1, 0, 2, 0, 3, 1, 0, 2, 1, 3, 0, 11, 
4, 3, 7, 1, 0 
2.14 0.005 < P < 0.01 
3 weeks before 0, 0, 1, 3, 5, 3, 0, 0, 0, 9, 3, 1, 0, 0, 1 1.73 0.01 < P < 0.02 
2 weeks before 3, 1, 2, 1, 2, 1, 6, 1, 0, 0, 0, 1, 2, 1 1.50 P ~ 0.01 
1 week before 0, 1, 1, 0, 0, 3, 2, 1, 1, 0, 2, 2, 1, 0, 1 1.00 0.001 < P < 0.002 
aPAA (0.25 mg) injected intraperitoneally. bVaccinia virus injected intravenously.  
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3. 5-Substituted 2’-deoxyuridines 
The 5-substituted 2’-deoxyuridines idoxuridine (5-iodo-dUrd, 5-iodo-2’-deoxyuridine, IDU) and 
trifluridine (5-trifluoro-2’-deoxythymidine, 5’-trifluoromethyl-dUrd, TFT) have been generally viewed 
as initiating the dawn of antiviral therapy, now 50 years ago [23]. In essence, this is because IDU and 
TFT later became the first licensed antiviral agents approved for the topical treatment (as eye drops 
and/or ointment) of herpetic keratitis [due to herpes simplex virus (HSV)]. It should not be ignored, 
however, that, while Prusoff [24] was the first to describe the synthesis of IDU, Herrmann [25] and 
Kaufman, Nesburn and Maloney [26] were the first to describe the inhibitory effects of IDU on 
vaccinia virus plaque formation in chick embryo cell cultures in vitro [25], and vaccinia virus infection 
of the rabbit cornea in vivo [26]. In fact, IDU and TFT would only be the first of a long list of  
5-substituted 2’-deoxyuridines [27,28], which also included 5-nitro-dUrd [29], 5-formyl-dUrd [30], 
and 5-ethyl-dUrd, 5-vinyl-dUrd and 5-ethynyl-dUrd [31], and which were all shown, in 1980, to 
inhibit VV replication in primary rabbit kidney cell cultures in vitro at an IC50 in the 0.1-1 µg/ml 
concentration range [31]. Ten years earlier, in 1969, Swierkowski and Shugar [32] had pointed to the 
importance of 5-ethyl-2’-deoxyuridine as an antiviral agent because it was considered nonmutagenic 
(in contrast with 5-iodo- and 5-bromo-2’-deoxyuridine). In 1965, Nemes and Hilleman [33] [the same 
Maurice Hilleman as magnificently depicted by Paul A. Offit in his book “Vaccinated. One Man’s 
Quest to Defeat the World’s Deadliest Diseases” [34]] described the effective treatment of herpetic 
keratitis with the new 5-substituted 2’-deoxyuridine 5-methylamino-2’-deoxyuridine (MADU); the 
antiviral activity of MADU roughly approximated that of IDU [33], but the tests were done with HSV, 
not VV. The largest series of 5-substituted 2’-deoxyuridines ever reviewed for their antiviral activity 
was that published in Mike Harnden’s book [35], but while the compounds were evaluated for their 
comparative activity against both HSV-1 and HSV-2, no data for VV were included [35]. 
Of the 5-substituted dUrd analogs, only IDU has been subject of an in-depth evaluation of its 
efficacy against VV infections in mice [36]. IDU had a protective effect in the VV tail lesion model 
(see supra) in immunocompetent mice, and in a lethal model for VV infection in SCID (severe 
combined immune deficiency) mice that had been infected with VV either intranasally, 
intraperitoneally or intravenously [36], but the dose at which IDU had to be given (subcutaneously) 
was relatively high (75-150 mg/kg/day), and when IDU was compared to cidofovir [(S)-HPMPC], the 
latter proved more efficacious at a lower dose (25 mg/kg/day) in its protective activity against 
intranasal VV infection in SCID mice [36]. 
4. Nucleoside analogs other than IDU and 5-substituted dUrd analogs 
In addition to the 5-substituted 2’-deoxyuridines, numerous other nucleoside analogs have been 
reported to inhibit VV at a sufficiently low IC50 (<1 µg/ml) to be potentially useful from a therapeutic 
viewpoint [27]: i.e., IMP (inosine 5’-monophosphate) dehydrogenase inhibitors, such as EICAR  
(5-ethynyl-1--D-ribofuranosylimidazole-4-carboxamide) [17]; SAH (S-adenosylhomocysteine 
hydrolase) inhibitors, such as neplanocin A [37], 3-deazaneplanocin A [21],  
9-(trans-2’,trans-3’-dihydroxycyclopent-4’-enyl)adenine (DHCeA) and -3-deazaadenine (c3DHCeA) 
[39], (1’R,2’S,3’R)-9-(2’,3’-dihydroxycyclopentan-1’-yl)adenine (DHCaA) and -3-deazaadenine 
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3
DHCaA) [40], (±)-6’-fluoroaristeromycin (F-C-Ado) [41], (±)-5’-noraristeromycin [42],  
(-)-5’-noraristeromycin [43], epi(-)-5’-noraristeromycin [44], (-)-3-deaza-5’-noraristeromycin [45], 
(R)-6’-C-methylneplanocin A [46], 6’-homoneplanocin A [47], and 2-fluoroneplanocin A [48]; 
carbocyclic cyclopentenyl cytosine (Ce-Cyd) [49,50], a putative inhibitor of CTP synthetase;  
8-methyladenosine [51], whose mechanism of action as an inhibitor of VV has never been clarified; 
the N-7-substituted acyclic nucleoside analog 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine 
S2242 [52], which is inhibitory to VV, as well as various herpesviruses (HSV, VZV, CMV), and 
whose antiviral activity, while depending on phosphorylation by deoxycytidine kinase (dCK) [53], was 
never fully elucidated; and adenine arabinoside, vidarabine (ara-A), the first antiviral drug to be 
approved for systemic use (for the treatment of VZV infections) [54], which is quite effective against 
VV replication in vitro [31] (the inhibition of VV replication by ara-A may be explained by the 
inhibitory effect of ara-ATP on viral DNA synthesis and/or a direct inhibitory effect of ara-A on SAH 
hydrolase, akin to that of all other adenosine analogs mentioned above (see supra). 
Figure 2. Large zone of inhibition without zone of toxicity. Cultures of chick fibroblast 
cells were seeded with approximately 500 plaque-forming units of vaccinia virus; the 
cylinder(s) were charged with 0.05 ml of solution of the substance tested (6-azauracil 
riboside)) (2.0 M); dishes of 4 cm diameter were employed. Figure taken from Rada, 
Blaškovič, Šorm and Škoda [57].  
 
 
Of the compounds listed above, very few were further explored for their in vivo activity against VV 
infection, and, when this was done, uniformly the pox tail lesion model was used: hence, this model 
allowed demonstration of the in vivo efficacy of EICAR [17], S2242 [18] and 3-deazaneplanocin A 
[21]. When no further in vivo testing was done with most of the compounds showing sufficient potency 
against VV in vitro, this must be attributed to the paucity of material available for such in vivo testing. 
In part C of my Stories in Antiviral Drug Discovery [55] I wrote that the first description of the 
antiviral activity of 6-azauridine dated back to 1977, thereby referring to the paper published by Rada 
and Dragun in Ann. N.Y. Acad. Sci. [56]. This is not entirely correct. Rada, Blaškovič, Šorm and 
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Škoda in 1960 (that is one year before Herrmann reported the plaque inhibition test for demonstrating 
the inhibitory effect of IDU on VV and HSV [25]) published a brief report in Experientia [57] on the 
inhibitory effect of 6-azauracil riboside on the multiplication of vaccinia virus (Figure 2). Rada et al. 
[57] also stated that 6-azauracil riboside had no direct inactivating effect on vaccinia virus and had no 
inhibitory effect on the multiplication of influenza virus, Newcastle disease virus (NDV) and Eastern 
equine encephalomyelitis virus when tested by the plaque method [57]. The mechanism of antiviral 
action of 6-azauridine was never fully elucidated. It has been assumed to interact, like pyrazofurin, at 
the level of the OMP decarboxylase [55]. 
5. The acyclic nucleoside phosphonates 
In 1986, we (Antonin Holý and I, and our colleagues) described the broad-spectrum anti-DNA 
virals, including anti-VV, activity of (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine  
[(S)-HPMPA] [58], and one year later, we extended these observations to various other 
phosphonylmethoxyalkyl derivatives of purines and pyrimidines, i.e., (S)-1-(3-hydroxy-2-
phosphonylmethoxypropyl)cytosine [(S)-HPMPC] [59] [(S)-HPMPC (cidofovir, Vistide®) would be 
licensed nine years later, in 1996, for the treatment of CMV retinitis in AIDS patients]. From the 
beginning, it was immediately clear that (S)-HPMPA and especially (S)-HPMPC (because it seemed to 
be less toxic in mice) had therapeutic potential as antiviral drugs [60]. The in vivo activity of  
(S)-HPMPA in the VV pox tail lesion model was already mentioned in the paper published in Antiviral 
Research in 1987 [59]. For (S)-HPMPC, we first focused on its efficacy in the therapy of experimental 
HSV infections in mice [61], before we described, in 1993, its efficacy in the treatment of VV 
infections in both normal, immunocompetent mice (based, again, on the VV pox tail lesion model) and 
immunodeficient (SCID) mice [62]. 
This was five years before orthopoxviruses, in particular variola, the etiological agent of smallpox, 
were, rather suddenly, felt as a bioterrorist public health threat [63,64]. This bioterrorist scenario 
prompted the search for an adequate therapy (or prophylaxis) to curb orthopoxvirus infections, and in 
the next few years several investigators (Bray et al., Smee et al.) found (S)-HPMPC (in the mean time 
better known as cidofovir) to protect mice against lethal respiratory infections with cowpox virus 
[65,66] and vaccinia virus [67,68]. Aerosolized cidofovir was found to be efficacious against 
aerosolized cowpox virus infection in mice [69], and cidofovir also proved efficacious in the treatment 
of mice infected with an highly virulent strain of ectromelia (mousepox virus) encoding  
interleukin-4 [70]. 
In a review on the potential of cidofovir in the treatment of poxvirus infections [71], I stated that 
cidofovir should be effective in the therapy and short-term prophylaxis of smallpox and related 
poxvirus infections in humans, as well as the treatment of the complications of vaccinia that may arise 
in immunocompromised patients inadvertently inoculated with the smallpox vaccine (vaccinia). With 
Johan Neyts and colleagues, I later demonstrated that cidofovir is indeed efficacious in the treatment of 
disseminated progressive vaccinia (in a mouse model); even when cidofovir treatment was initiated at 
the time disseminated vaccinia had developed, it caused lesions to heal and regress (Figure 3) [72,73].  
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Figure 3. Effect of systemically administered cidofovir on disseminated vaccinia when 
therapy was initiated on day 15 p.i. (A) Progression of cutaneous vaccinia in three mock-
treated animals. Mice 1 and 3 died on day 35 p.i.; mouse 2 died on day 36 p.i. (B) Effect of 
subcutaneous treatment with cidofovir (at 100 mg/kg/day), initiated on day 15 p.i., on 
disseminated cutaneous vaccinia lesions. Cidofovir was given for 21 days (over a period of 
24 days). Figure taken from Neyts, Leyssen, Verbeken and De Clercq [72,73]. 
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6. Oral alkoxyalkyl prodrugs of acyclic nucleoside phosphonates 
An additional advantage of cidofovir is that it is not only active against orthopoxviruses, but also 
parapoxviruses [such as orf (ecthyma contagiosum)] and molluscipoxviruses (such as molluscum 
contagiosum), which may both lead to serious infections in immunocompromised patients (in fact, 
anecdotal reports suggest that cidofovir is clinically efficacious against orf and molluscum 
contagiosum [71,74,75]). However, cidofovir, like all other acyclic nucleoside phosphonates [76], 
suffers from the disadvantage that it has poor oral bioavailability. This explains why alkoxyalkyl  
[i.e., hexadecyloxypropyl (HDP) and octadecyloxyethyl (ODE)] prodrugs of cidofovir (HDP-CDV and 
ODE-CDV) were developed [77], intentionally as oral medicines for the prophylaxis and therapy of 
smallpox infection [78]. Esterification of cidofovir with alkoxyalkanols not only increases its oral 
bioavailability but also diminishes drug accumulation in the kidney [79], and thus reduces 
nephrotoxicity [77]. In molecular terms, HDP-CDV is rapidly taken up in the cells thanks to a rapid 
association with cellular membrane phospholipids [80]. This results in enhanced inhibition of 
orthopoxvirus (i.e., vaccinia virus and cowpox virus) replication in vitro [81,82]. Increased in vivo 
activity of HDP-CDV and ODE-CDV, over that of CDV, has also been demonstrated in mice infected 
with vaccinia virus (VV) or cowpox virus (CV) [83], or ectromelia (mousepox) virus [84]. 
Following the same reasoning as for cidofovir, alkoxyalkyl (i.e., HDP and ODE) derivatives have 
also been prepared from (S)-HPMPA, the prototype of the acyclic nucleoside phosphonates [58]. When 
compared with the alkoxyalkyl esters of cidofovir, the corresponding alkoxyalkyl esters of (S)-
HPMPA were equally active against CMV but were 15- to 20-fold more active against VV and CV in 
vitro [85]. In vivo, oral treatment with HDP-(S)-HPMPA or ODE-(S)-HPMPA were highly effective 
against lethal VV or CV infections in mice [86]. Thus, alkoxyalkyl prodrugs of both cidofovir and  
(S)-HPMPA can be considered excellent candidates for the oral treatment (and prophylaxis) of 
smallpox in humans, should this prove necessary in the event of a bioterrorist release of the variola 
virus (HDP-CDV is also referred to as CMX001 [78]). 
7. ST-246, an orally bioavailable antipoxvirus compound, that inhibits extracellular virus 
formation 
Following a totally new strategy (different from the nucleoside or nucleotide analogs), Dennis 
Hruby and his colleagues at SIGA Technologies in Corvallis (Oregon) came up with a new class of 
orthopoxvirus (i.e., vaccinia virus) antiviral drugs (i.e., TTP-6171) that block viral maturation [87]. 
These drugs block viral maturation through an interaction with the VV I7L gene product, a cysteine 
proteinase responsible for cleavage of the three major core protein precursors [88] and, hence, the 
production of infectious virions [89]. The reported compound, TTP-6171, was not further pursued as a 
potentially antiviral drug, in favor of a newly discovered compound, ST-246, that appeared to inhibit 
extracellular orthopoxvirus formation (and to protect mice from a lethal orthopoxvirus challenge) [90], 
apparently as the result of an action targeted at the F13L protein (phospholipase) which had previously 
[91] been recognized as a major membrane component of extracellular vaccinia virus. 
ST-246, or 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-etheno-cycloprop-
(f)isoindol-2-(1H-yl)benzamide [92] was shown to have activity against a number of orthopoxviruses, 
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including vaccinia, monkeypox, camelpox, cowpox, ectromelia (mousepox) and variola virus [90]. ST-
246 has proven effective against vaccinia, cowpox, and camelpox viruses in human embryonic lung 
and primary human keratinocyte cell monolayers, as well as three-dimensional organotypic raft 
cultures [93]. In vivo efficacy of ST-246 has been demonstrated in mice infected with vaccinia virus 
[90] or ectromelia virus (even if treatment was delayed until 72 hours after virus infection [94]), and in 
ground squirrels infected with monkeypox virus [95]. ST-246 is also effective against aerosolized 
rabbit pox in rabbits [96], and acts synergistically with CMX001 (HDP-CDV) in mice infected with 
cowpox virus [97], which opens new avenues for the treatment of orthopoxvirus infections. 
Most important is to know whether ST-246 would be effective against smallpox (bioterrorist attack) 
or the complications of smallpox vaccination (such as eczema vaccinatum). A recent case of severe 
eczema vaccinatum in a household contact (28-month-old son) of a smallpox vaccinee illustrates the 
risks for such adverse events [98]. The boy eventually recovered after treatment with vaccinia immune 
globulin, cidofovir, and ST-246 [98]. What exactly saved the boy’s life - the antibody, cidofovir, ST-
246, or the extraordinary medical care, or combinations of some or all of the above - would never be 
known. 
Recently, ST-246 has been found to protect non-human primates from smallpox virus or 
monkeypox virus [99]. ST-246 has, in the mean time, been renamed tecovirimat [100] and its target 
protein, F13L, is also known as p37. It is further developed by SIGA Technologies for the treatment of 
variola virus infection (smallpox) [100]. 
8. Cellular kinases as targets for anti-orthopoxvirus therapy 
Among the various agents that could be considered potentially useful in the therapy of 
(ortho)poxvirus infections [101], also rank a few compounds that are targeted at cellular (tyrosine) 
kinases, and thus could inhibit poxvirus infections through inhibition of cellular signal transduction, 
i.e., CI-1033 and related 4-anilinoquinazolines [102] and STI-571 (imatinib, better known as Gleevec 
or Glivec) [103]. Gleevec has been licensed for clinical use as an anticancer agent, to treat chronic 
myeloid leukemia. That it would also have the ability to inhibit poxvirus infections (by blocking the 
egress of these viruses from infected cells) [103] is an unanticipated attribute [104]. Thus, Gleevec 
casts “a pox on poxviruses” [104], but although the findings of Reeves et al. [103] date from five years 
back, the potential utility of Gleevec, or tyrosine kinase inhibitors in general, in the treatment of 
poxvirus infections like smallpox, monkeypox, or the complications associated with vaccinia virus 
vaccination, still remains to be substantiated. 
9. Camelpox virus, the orthopoxvirus most closely related to variola virus 
Of all the (ortho)poxviruses, camelpox virus, the etiologic agent of camelpox occurring in Old 
World camels (Camelus dromedarius and Camelus bactrianus), is the orthopoxvirus most closely 
related to variola virus, the cause of smallpox [105]. Studies with camelpox virus (which is not 
supposed to be pathogenic for humans) have allowed confirmation of the anti-poxvirus activity of the 
“older” acyclic nucleoside phosphonates such as (S)-HPMPA and (S)-HPMPC [106], but also to 
extend the anti-camelpox virus activity to the “newer” acyclic nucleoside phosphonates such as  
(R)-{2,4-diamino-3-hydroxy-6-[2-(phosphonomethoxy)propopy]}pyrimidine [(R)-HPMPO-DAPy] and 
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1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine (HPMP-5-azaC) [107]. As already 
mentioned above [93], the anti-(ortho)poxvirus activity of ST-246 also extends to camelpox virus, 
although camelpox, vaccinia, and cowpox show different levels of sensitivity to ST-246, probably 
because of dissimilarities between their ways of propagation [108]. 
10. Epilogue: antiviral treatment more effective than smallpox vaccination 
Figure 4. Kaplan-Meier plot showing the effect of different post-exposure treatments on 
the survival of monkeys. Survival expressed as percentages after intratracheal MPXV 
infection. After virus exposure, macaques were sham-treated (group I), vaccinated with 
smallpox vaccine Elstree-RIVM (group II), treated with 5 doses of cidofovir (group III), 
with six doses of cidofovir (group IV), with five doses of HPMPO-DAPy (group V) or 
with six doses of HPMPO-DAPy (group VI). Arrowheads indicate times of vaccination 
and antiviral treatment. *The control group is supplemented with 11 animals from previous 
experiments. Figure taken from Stittelaar et al. [109]. 
 
 
Although the preventive use of smallpox vaccination is well documented, little is known about its 
efficacy when used after exposure to variola virus. A few years ago, we (Albert Osterhaus and I, and 
our colleagues) wanted to compare the effectiveness of post-exposure smallpox vaccination and 
antiviral treatment with either cidofovir [(S)-HPMPC] or the related acyclic nucleoside phosphonate 
analog (R)-HPMPO-DAPy, at 24 hours after lethal intratracheal infection of cynomolgus monkeys 
(Macaca fascicularis) with monkeypox virus. This study was actually planned after I had met Koert 
Stittelaar at a meeting in London (“Twenty-five years on: smallpox revisited”, Retroscreen Virology 
and Institute of Cell and Molecular Sciences Barts and the London Queen Mary’s School of Medicine 
& Dentistry, The Great Hall, St. Bartholomew’s Hospital, London, Great Britain, 31 October 2003). 
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This study, published in 2006 in Nature [109] clearly revealed that initiation of antiviral treatment with 
either cidofovir or (R)-HPMPO-DAPy at 24 hours after monkeypox virus infection resulted in 
significantly reduced mortality (Figure 4). In contrast, when monkeys were vaccinated at 24 hours 
after virus infection, using a standard human dose of a currently recommended smallpox vaccine 
(Elstree), no significant reduction in mortality was observed [109]. From this study [109], we 
concluded “that adequate preparedness for a biological threat involving smallpox should include the 
possibility of treating exposed individuals with antiviral compounds such as cidofovir or other 
selective anti-poxvirus drugs”. 
Acknowledgments 
I am most grateful to Christiane Callebaut for her proficient editorial assistance. 
References and Notes 
1. Bauer, D.J. Introduction to antiviral chemotherapy. In Chemotherapy of Virus Diseases; Bauer, 
D.J., Ed.; Pergamon Press: Oxford, UK, 1972; Volume 1, pp. 1-33. 
2. Domagk, G.; Behnisch, R.; Mietzch, F.; Schmidt, H. Über eine neue, gegen Tuberkelbazillen in 
vitro wirksame Verbindungsklasse. Naturwissenschaften 1946, 10, 315. 
3. Hamre, D.; Bernstein, J.; Donovick, R. Activity of p-aminobenzaldehyde, 3-thiosemicarbazone on 
vaccinia virus in the chick embryo and in the mouse. Proc. Soc. Exp. Biol. Med. 1950, 73,  
275-278. 
4. Hamre, D.; Brownlee, K.A.; Donovick, R. Studies on the chemotherapy of vaccinia virus. II. The 
activity of some thiosemicarbazones. J. Immunol. 1951, 67, 305-312. 
5. Thompson, R.L.; Price, M.L.; Minton, S.A. Jr. Protection of mice against vaccinia virus by 
administration of benzaldehyde thiosemicarbazone. Proc. Soc. Exp. Biol. Med. 1951, 78, 11-13. 
6. Bauer, D.J. Thiosemicarbazones. In Chemotherapy of Virus Diseases; Bauer, D.J., Ed.; Pergamon 
Press: Oxford, UK, 1972; Volume 1, pp. 35-113. 
7. Thompson, R.L.; Minton, S.A., Jr.; Officer, J.E.; Hitchings, G.H. Effect of heterocyclic and other 
thiosemicarbazones on vaccinia infection in the mouse. J. Immunol. 1953, 70, 229-234. 
8. Thompson, R.L.; Davis, J.; Russell, P.B.; Hitchings, G.H. Effect of aliphatic oxime and isatin 
thiosemicarbazone on vaccinia infection in the mouse and in the rabbit. Proc. Soc. Exp. Biol. Med. 
1953, 84, 496-499. 
9. Bauer, D.J. The antiviral and synergic actions of isatin thiosemicarbazone and certain 
phenoxypyrimidines in vaccinia infection in mice. Br. J. Exp. Pathol. 1955, 36, 105-114. 
10. Bauer, D.J.; St. Vincent, L.; Kempe, C.H.; Downie, A.W. Prophylactic treatment of small pox 
contacts with N-methylisatin -thiosemicarbazone (compound 33T57, Marboran). Lancet 1963, 2, 
494-496. 
11. De Clercq, E.; De Somer, P. Effect of interferon, polyacrylic acid, and polymethacrylic acid on 
tail lesions on mice infected with vaccinia virus. Appl. Microbiol. 1968, 16, 1314-1319. 
12. Boyle, J.J.; Haff, R.F.; Stewart, R.C. 1967. Evaluation of antiviral compounds by suppression of 
tail lesions in vaccinia-infected mice. Antimicrob. Agents Chemother. 1966, 6, 536-539. 
Viruses 2010, 2                            
 
 
1333 
13. De Clercq, E.; Luczak, M.; Shugar, D.; Torrence, P.F.; Waters, J.A.; Witkop, B. Effect of 
cytosine, arabinoside, iododeoxyuridine, ethyldeoxyuridine, thiocyanatodeoxyuridine, and 
ribavirin on tail lesion formation in mice infected with vaccinia virus. Proc. Soc. Exp. Biol. Med. 
1976, 151, 487-490. 
14. De Clercq, E.; Bergstrom, D.E.; Holý, A.; Montgomery, J.A. Broad-spectrum antiviral activity of 
adenosine analogs. Antiviral Res. 1984, 4, 119-133. 
15. Van Aerschot, A.; Herdewijn, P.; Janssen, G.; Cools, M.; De Clercq, E. Synthesis and antiviral 
activity evaluation of 3'-fluoro-3'-deoxyribonucleosides: broad-spectrum antiviral activity of 3'-
fluoro-3'-deoxyadenosine. Antiviral Res. 1989, 12, 133-150. 
16. De Clercq, E.; Holý, A.; Rosenberg, I. Efficacy of phosphonylmethoxyalkyl derivatives of 
adenine in experimental herpes simplex virus and vaccinia virus infections in vivo. Antimicrob. 
Agents Chemother. 1989, 33, 185-191. 
17. De Clercq, E.; Cools, M.; Balzarini, J.; Snoeck, R.; Andrei, G.; Hosoya, M.; Shigeta, S.; Ueda, T.; 
Minakawa, N.; Matsuda, A. Antiviral activities of 5-ethynyl-1-beta-D-ribofuranosylimidazole-4- 
carboxamide and related compounds. Antimicrob. Agents Chemother. 1991, 35, 679-684. 
18. Neyts, J.; De Clercq, E. Efficacy of 2-amino-7-(1,3-dihydroxy-2-propoxymethyl)purine for 
treatment of vaccinia virus (orthopoxvirus) infections in mice. Antimicrob. Agents Chemother. 
2001, 45, 84-87. 
19. Tignor, G.H.; Kende, M.; Hanham, C.A. Chemotherapeutic prevention of complications caused 
by vaccinia virus-vectored immunogen. Ann. N.Y. Acad. Sci. 1992, 653, 334-343. 
20. Walton, E.; Jenkins, S.R.; Nutt, R.F.; Holly, F.W. Branched-chain sugar nucleosides. V. Synthesis 
and antiviral properties of several branched-chain sugar nucleosides. J. Med. Chem. 1969, 12, 
306-309. 
21. Tseng, C.K.H.; Marquez, V.E.; Fuller, R.W.; Goldstein, B.M.; Haines, D.R.; McPherson, H.; 
Parsons, J.L.; Shannon, W.M.; Arnett, G. Synthesis of 3-deazaneplanocin A, a powerful inhibitor 
of S-adenosylhomocysteine hydrolase with potent and selective in vitro and in vivo antiviral 
activities. J. Med. Chem. 1989, 32, 1442-1446. 
22. Smee, D.F.; Sidwell, R.W. A review of compounds exhibiting anti-orthopoxvirus activity in 
animal models. Antiviral Res. 2003, 57, 41-52. 
23. De Clercq, E. Looking back in 2009 at the dawning of antiviral therapy now 50 years ago: an 
historical perspective. Adv. Virus Res. 2009, 73, 1-53. 
24. Prusoff, W.H. Synthesis and biological activities of iododeoxyuridine, an analog of thymidine. 
Biochim. Biophys. Acta 1959, 32, 295-296. 
25. Herrmann, E.C. Jr. Plaque inhibition test for detection of specific inhibitors of DNA containing 
viruses. Proc. Soc. Exp. Biol. Med. 1961, 107, 142-145. 
26. Kaufman, H.E.; Nesburn, A.B.; Maloney, E.D. Cure of vaccinia infection by 5-iodo-2’-
deoxyuridine. Virology 1962, 18, 567-569. 
27. De Clercq, E. Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections. 
Clin. Microbiol. Rev. 2001, 14, 382-397. 
28. De Clercq, E. Antiviral and antitumor activities of 5-substituted 2’-deoxyuridines. Meth. Find. 
Exptl. Clin. Pharmacol. 1980, 2, 253-267. 
Viruses 2010, 2                            
 
 
1334 
29. De Clercq, E.; Descamps, J.; Huang, G.F.; Torrence, P.F. 5-Nitro-2'-deoxyuridine and 5-nitro-2'-
deoxyuridine 5'-monophosphate: antiviral activity and inhibition of thymidylate synthetase in 
vivo. Mol. Pharmacol. 1978, 14, 422-430. 
30. De Clercq, E.; Descamps, J.; Schmidt, C.L.; Mertes, M.P. Antiviral activity of 5-
methylthiomethyl-2'-deoxyuridine and other 5-substituted 2'-deoxyuridines. Biochem. Pharmacol. 
1979, 28, 3249-3254. 
31. De Clercq, E.; Descamps, J.; Verhelst, G.; Walker, R.T.; Jones, A.S.; Torrence, P.F.; Shugar, D. 
Comparative efficacy of antiherpes drugs against different strains of herpes simplex virus.  
J. Infect. Dis. 1980, 141, 563-574. 
32. Swierkowski, M.; Shugar, D. A nonmutagenic thymidine analog with antiviral activity.  
5-Ethyldeoxyuridine. J. Med. Chem. 1969, 12, 533-534. 
33. Nemes, M.M.; Hilleman, M.R. Effective treatment of experimental herpes simplex keratitis with 
new derivative, 5-methylamino-2’-deoxyuridine (MADU). Proc. Soc. Exp. Biol. Med. 1965, 119, 
515-520. 
34. Offit, P.A., Vaccinated. One Man’s Quest to Defeat the World’s Deadliest Diseases; 
HarperCollins Publishers Inc: New York, NY, USA, 2007; pp. 1-254. 
35. De Clercq, E. Synthetic pyrimidine nucleoside analogs. In Approaches to Antiviral Agents; 
Harnden, M.R., Ed.; MacMillan, London, United Kingdom, 1985; pp. 57-99. 
36. Neyts, J.; Verbeken, E.; De Clercq, E. Effect of 5-iodo-2’-deoxyuridine on vaccinia virus 
(orthopoxvirus) infections in mice. Antimicrob. Agents Chemother. 2002, 46, 2842-2847. 
37. De Clercq, E. Antiviral and antimetabolic activities of neplanocins. Antimicrob. Agents 
Chemother. 1985, 28, 84-89. 
38. De Clercq, E.; Cools, M.; Balzarini, J.; Marquez, V.E.; Borcherding, D.R.; Borchardt, R.T.; 
Drach, J.C.; Kitaoka, S.; Konno, T. Broad-spectrum antiviral activities of neplanocin A,  
3-deazaneplanocin A, and their 5'-nor derivatives. Antimicrob. Agents Chemother. 1989, 33,  
1291-1297. 
39. Hasobe, M.; McKee, J.G.; Borcherding, D.R.; Borchardt, R.T.  
9-(trans-2',trans-3'-Dihydroxycyclopent-4'-enyl)-adenine and -3-deazaadenine: analogs of 
neplanocin A which retain potent antiviral activity but exhibit reduced cytotoxicity. Antimicrob. 
Agents Chemother. 1987, 31, 1849-1851. 
40. Hasobe, M.; Liang, H.; Ault-Riche, D.B.; Borcherding, D.R.; Wolfe, M.S.; Borchardt, R.T. 
(1’R,2’S,3’R)-9-(2’,3’-Dihydroxycyclopentan-1’-yl)-adenine and -3-deaza-adenine: analogs of 
aristeromycin which exhibit potent antiviral activity with reduced cytotoxicity. Antiviral Chem. 
Chemother. 1993, 4, 245-248. 
41. Cools, M.; Balzarini, J.; De Clercq, E. Mechanism of antiviral and cytotoxic action of (±)-6' beta-
fluoroaristeromycin, a potent inhibitor of S-adenosylhomocysteine hydrolase. Mol. Pharmacol. 
1991, 39, 718-724. 
42. Patil, S.D.; Schneller, S.W.; Hosoya, M.; Snoeck, R.; Andrei, G.; Balzarini, J.; De Clercq, E. 
Synthesis and antiviral properties of (±)-5'-noraristeromycin and related purine carbocyclic 
nucleosides. A new lead for anti-human cytomegalovirus agent design. J. Med. Chem. 1992, 35, 
3372-3377. 
Viruses 2010, 2                            
 
 
1335 
43. Siddiqi, S.M.; Chen, X.; Schneller, S.W.; Ikeda, S.; Snoeck, R.; Andrei, G.; Balzarini, J.; De 
Clercq, E. Antiviral enantiomeric preference for 5'-noraristeromycin. J. Med. Chem. 1994, 37, 
551-554. 
44. Siddiqi, S.M.; Chen X.; Schneller, S.W.; Ikeda, S.; Snoeck, R.; Andrei, G.; Balzarini, J.; De 
Clercq E. An epimer of 5’-norartisteromycin and its antiviral properties. J. Med. Chem. 1994, 37, 
1382-1384; 
45. Siddiqi, S.M.; Chen, X.; Rao, J.; Schneller, S.W.; Ikeda, S.; Snoeck, R.; Andrei, G.; Balzarini, J.; 
De Clercq, E. 3-deaza- and 7-deaza-5'-noraristeromycin and their antiviral properties. J. Med. 
Chem. 1995, 38, 1035-1038. 
46. Shuto, S.; Obara, T.; Toriya, M.; Hosoya, M.; Snoeck, R.; Andrei, G.; Balzarini, J.; De Clercq, E. 
New neplanocin analogs. 1. Synthesis of 6'-modified neplanocin A derivatives as broad-spectrum 
antiviral agents. J. Med. Chem. 1992, 35, 324-331. 
47. Shuto, S.; Obara, T.; Saito, Y.; Andrei, G.; Snoeck, R.; De Clercq, E.; Matsuda, A. New 
neplanocin analogs. 6. Synthesis and potent antiviral activity of 6'-homoneplanocin A1.  
J. Med. Chem. 1996, 39, 2392-2399. 
48. Obara, T.; Shuto, S.; Saito, Y.; Snoeck, R.; Andrei, G.; Balzarini, J.; De Clercq, E.; Matsuda, A. 
New neplanocin analogs. 7. Synthesis and antiviral activity of 2-halo derivatives of neplanocin A. 
J. Med. Chem. 1996, 39, 3847-3852. 
49. De Clercq, E.; Murase, J.; Marquez, V.E. Broad-spectrum antiviral and cytocidal activity of 
cyclopentenylcytosine, a carbocyclic nucleoside targeted at CTP synthetase. Biochem. Pharmacol. 
1991, 41, 1821-1829. 
50. Marquez, V.E.; Lim, M.I.; Treanor, S.P.; Plowman, J.; Priest, A.; Markovac, A.; Khan, M.S.; 
Kaskar, B.; Driscoll, J.S. Cyclopentenylcytosine. A carbocyclic nucleoside with antitumor and 
antiviral properties. J. Med. Chem. 1988, 31, 1687-1694. 
51. Van Aerschot, A.A.; Mamos, P.; Weyns, N.J.; Ikeda, S; De Clercq, E.; Herdewijn, P.A. Antiviral 
activity of C-alkylated purine nucleosides obtained by cross-coupling with tetraalkyltin reagents. 
J. Med. Chem. 1993, 36, 2938-2942. 
52. Neyts, J.; Andrei, G.; Snoeck, R.; Jähne, G.; Winkler, I.; Helsberg, M.; Balzarini, J.; De Clercq, E. 
The N-7-substituted acyclic nucleoside analog 2-amino-7- 
[(1,3-dihydroxy-2-propoxy)methyl]purine is a potent and selective inhibitor of herpesvirus 
replication. Antimicrob. Agents Chemother. 1994, 38, 2710-2716. 
53. Neyts, J.; Balzarini, J.; Andrei, G.; Chaoyong, Z.; Snoeck, R.; Zimmermann, A.; Mertens, T.; 
Karlsson, A.; De Clercq, E. Intracellular metabolism of the N7-substituted acyclic nucleoside 
analog 2-amino-7-(1,3-dihydroxy-2-propoxymethyl)purine, a potent inhibitor of herpesvirus 
replication. Mol. Pharmacol. 1998, 53, 157-165. 
54. Whitley, R.J.; Ch'ien, L.T.; Dolin, R.; Galasso, G.J.; Alford, C.A. Jr. Adenine arabinoside therapy 
of herpes zoster in the immunosuppressed. NIAID collaborative antiviral study. N. Engl. J. Med. 
1976, 294, 1193-1199. 
55. De Clercq, E. Another ten stories in antiviral drug discovery (part C): "Old" and "new" antivirals, 
strategies, and perspectives. Med. Res. Rev. 2009, 29, 611-645. 
56. Rada, B.; Dragún, M. Antiviral action and selectivity of 6-azauridine. Ann. N.Y. Acad. Sci. 1977, 
284, 410-417. 
Viruses 2010, 2                            
 
 
1336 
57. Rada, B.; Blaškovič, D.; Šorm, F.; Škoda, J. The inhibitory effect of 6-azauracil riboside on the 
multiplication of vaccinia virus. Experientia 1960, 16, 487-488. 
58. De Clercq, E.; Holý, A.; Rosenberg, I.; Sakuma, T.; Balzarini, J.; Maudgal, P.C. A novel selective 
broad-spectrum anti-DNA virus agent. Nature 1986, 323, 464-467. 
59. De Clercq, E.; Sakuma, T.; Baba, M.; Pauwels, R.; Balzarini, J.; Rosenberg, I.; Holý, A. Antiviral 
activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antiviral Res. 1987, 8, 
261-272. 
60. De Clercq, E. Therapeutic potential of HPMPC as an antiviral drug. Rev. Med. Virol. 1993, 3,  
85-96. 
61. De Clercq, E.; Holý, A. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine in 
various models of herpes simplex virus infection in mice. Antimicrob. Agents Chemother. 1991, 
35, 701-706. 
62. Neyts, J.; De Clercq, E. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine for 
the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) 
mice. J. Med. Virol. 1993, 41, 242-246. 
63. Henderson, D.A. Bioterrorism as a public health threat. Emerg. Infect. Dis. 1998, 4, 488-492. 
64. Breman, J.G.; Henderson, D.A. Poxvirus dilemmas--monkeypox, smallpox, and biologic 
terrorism. N. Engl. J. Med. 1998, 339, 556-559. 
65. Bray, M.; Martinez, M.; Smee, D.F.; Kefauver, D.; Thompson, E.; Huggins, J.W. Cidofovir 
protects mice against lethal aerosol or intranasal cowpox virus challenge. J. Infect. Dis. 2000, 181, 
10-19. 
66. Smee, D.F.; Bailey, K.W.; Wong, M.-H.; Sidwell, R.W. Intranasal treatment of cowpox virus 
respiratory infections in mice with cidofovir. Antiviral Res. 2000, 47, 171-177. 
67. Smee, D.F.; Bailey, K.W.; Wong, M.-H.; Sidwell, R.W. Effects of cidofovir on the pathogenesis 
of a lethal vaccinia virus respiratory infection in mice. Antiviral Res. 2001, 52, 55-62. 
68. Smee, D.F.; Bailey, K.W.; Sidwell, R.W. Treatment of lethal vaccinia virus respiratory infections 
in mice with cidofovir. Antiviral Chem. Chemother. 2001, 12, 71-76. 
69. Bray, M.; Martinez, M.; Kefauver, D.; West, M.; Roy, C. Treatment of aerosolized cowpox virus 
infection in mice with aerosolized cidofovir. Antiviral Res. 2002, 54, 129-142. 
70. Robbins, S.J.; Jackson, R.J.; Fenner, F.; Beaton, S.; Medveczky, J.; Ramshaw, I.A.; Ramsay, A.J. 
The efficacy of cidofovir treatment of mice infected with ectromelia (mousepox) virus encoding 
interleukin-4. Antiviral Res. 2005, 66, 1-7. 
71. De Clercq, E. Cidofovir in the treatment of poxvirus infections. Antiviral Res. 2002, 55, 1-13. 
72. Neyts, J.; Leyssen, P.; Verbeken, E.; De Clercq, E. Efficacy of cidofovir in a murine model of 
disseminated progressive vaccinia. Antimicrob. Agents Chemother. 2004, 48, 2267-2273. 
73. De Clercq, E.; Neyts, J. Therapeutic potential of nucleoside/nucleotide analogs against poxvirus 
infections. Rev. Med. Virol. 2004, 14, 289-300. 
74. Geerinck, K.; Lukito, G.; Snoeck, R; De Vos, R.; De Clercq, E.; Vanrenterghem, Y.; Degreef, H.; 
Maes, B. A case of human orf in an immunocompromised patient treated successfully with 
cidofovir cream. J. Med. Virol. 2001, 64, 543-549. 
Viruses 2010, 2                            
 
 
1337 
75. Fery-Blanco, C.; Pelletier, F.; Humbert, P.; Aubin, F. Disseminated molluscum contagiosum 
during topical treatment of atopic dermatitis with tacrolimus: efficacy of cidofovir. Ann. 
Dermatol. Venereol. 2007, 134, 457-459. 
76. De Clercq, E.; Holý, A. Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nat. Rev. 
Drug Discov. 2005, 4, 928-940. 
77. Hostetler, K.Y. Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral 
activity and reduce toxicity: current state of the art. Antiviral Res. 2009, 82, A84-A98. 
78. Painter, G.R.; Hostetler, K.Y. Design and development of oral drugs for the prophylaxis and 
treatment of smallpox infection. Trends Biotechnol. 2004, 22, 423-427. 
79. Ciesla, S.L.; Trahan, J.; Wan, W.B.; Beadle, J.R.; Aldern, K.A.; Painter, G.R.; Hostetler, K.Y. 
Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug 
accumulation in kidney. Antiviral Res. 2003, 59, 163-171. 
80. Aldern, K.A.; Ciesla, S.L.; Winegarden, K.L.; Hostetler, K.Y. Increased antiviral activity of 1-O-
hexadecyloxypropyl-[2-(14)C]cidofovir in MRC-5 human lung fibroblasts is explained by unique 
cellular uptake and metabolism. Mol. Pharmacol. 2003, 63, 678-681. 
81. Kern, E.R.; Hartline, C.; Harden, E.; Keith, K.; Rodriguez, N.; Beadle, J.R.; Hostetler, K.Y. 
Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and 
cyclic cidofovir. Antimicrob. Agents Chemother. 2002, 46, 991-995. 
82. Keith, K.A.; Wan, W.B.; Ciesla, S.L.; Beadle, J.R.; Hostetler, K.Y.; Kern, E.R. Inhibitory activity 
of alkoxyalkyl and alkyl esters of cidofovir and cyclic cidofovir against orthopoxvirus replication 
in vitro. Antimicrob. Agents Chemother. 2004, 48, 1869-1871. 
83. Quenelle, D.C.; Collins, D.J.; Wan, W.B.; Beadle, J.R.; Hostetler, K.Y.; Kern, E.R. Oral treatment 
of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir. Antimicrob. 
Agents Chemother. 2004, 48, 404-412. 
84. Buller, R.M.; Owens, G.; Schriewer, J.; Melman, L.; Beadle, J.R.; Hostetler, K.Y. Efficacy of oral 
active ether lipid analogs of cidofovir in a lethal mousepox model. Virology 2004, 318, 474-481. 
85. Beadle, J.R.; Wan, W.B.; Ciesla, S.L.; Keith, K.A.; Hartline, C.; Kern, E.R.; Hostetler, K.Y. 
Synthesis and antiviral evaluation of alkoxyalkyl derivatives of 9-(S)-(3-hydroxy-2-
phosphonomethoxypropyl)adenine against cytomegalovirus and orthopoxviruses. J. Med. Chem. 
2006, 49, 2010-2015. 
86. Quenelle, D.C.; Collins, D.J.; Herrod, B.P.; Keith, K.A.; Trahan, J.; Beadle, J.R.; Hostetler, K.Y.; 
Kern, E.R. Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- 
phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox 
or vaccinia virus infections in mice. Antimicrob. Agents Chemother. 2007, 51, 3940-3947. 
87. Byrd, C.M.; Bolken, T.C.; Mjalli, A.M.; Arimilli, M.N.; Andrews, R.C.; Rothlein, R.; Andrea, T.; 
Rao, M.; Owens, K.L.; Hruby, D.E. New class of orthopoxvirus antiviral drugs that block viral 
maturation. J. Virol. 2004, 78, 12147-12156. 
88. Byrd, C.M.; Bolken, T.C.; Hruby, D.E. Molecular dissection of the vaccinia virus I7L core protein 
proteinase. J. Virol. 2003, 77, 11279-11283. 
89. Byrd, C.M.; Bolken, T.C.; Hruby, D.E. The vaccinia virus I7L gene product is the core protein 
proteinase. J. Virol. 2002, 76, 8973-8976. 
Viruses 2010, 2                            
 
 
1338 
90. Yang, G.; Pevear, D.C.; Davies, M.H.; Collett, M.S.; Bailey, T.; Rippen, S.; Barone, L.; Burns, 
C.; Rhodes, G.; Tohan, S.; Huggins, J.W.; Baker, R.O.; Buller, R.L.; Touchette, E.; Waller, K.; 
Schriewer, J.; Neyts, J.; De Clercq, E.; Jones, K.; Hruby, D.; Jordan, R. An orally bioavailable 
antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from 
lethal orthopoxvirus challenge. J. Virol. 2005, 79, 13139-13149. 
91. Husain, M.; Weisberg, A.; Moss, B. Topology of epitope-tagged F13L protein, a major membrane 
component of extracellular vaccinia virions. Virology 2003, 308, 233-242. 
92. Bailey, T.R.; Rippin, S.R.; Opsitnick, E.; Burns, C.J.; Pevear, D.C.; Collett, M.S.; Rhodes, G.; 
Tohan, S.; Huggins, J.W.; Baker, R.O.; Kern, E.R.; Keith, K.A.; Dai, D.; Yang, G.; Hruby, D.; 
Jordan, R. N-(3,3a,4,4a,5,5a,6,6a-Octahydro-1,3-dioxo-4,6- ethenocycloprop[f]isoindol-2-(1H)-
yl)carboxamides: Identification of novel orthopoxvirus egress inhibitors. J. Med. Chem. 2007, 50, 
1442-1444. 
93. Duraffour, S.; Snoeck, R.; de Vos, R.; van Den Oord, J.J.; Crance, J.M; Garin, D.; Hruby, D.E.; 
Jordan, R.; De Clercq, E.; Andrei, G. Activity of the anti-orthopoxvirus compound ST-246 against 
vaccinia, cowpox and camelpox viruses in cell monolayers and organotypic raft cultures. Antivir. 
Ther. 2007, 12, 1205-1216. 
94. Quenelle, D.C.; Buller, R.M.; Parker, S.; Keith, K.A.; Hruby, D.E.; Jordan, R.; Kern, E.R. 
Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections 
in mice. Antimicrob. Agents Chemother. 2007, 51, 689-695. 
95. Sbrana, E.; Jordan, R.; Hruby, D.E.; Mateo, R.I.; Xiao, S.Y.; Siirin, M.; Newman, P.C.; Travassos 
Da Rosa, A.P.A.; Tesh, R.B. Efficacy of the antipoxvirus compound ST-246 for treatment of 
severe orthopoxvirus infection. Am. J. Trop. Med. Hyg. 2007, 76, 768-773. 
96. Nalca, A.; Hatkin, J.M.; Garza, N.L.; Nichols, D.K.; Norris, S.W.; Hruby, D.E.; Jordan, R. 
Evaluation of orally delivered ST-246 as postexposure prophylactic and antiviral therapeutic in an 
aerosolized rabbitpox rabbit model. Antiviral Res. 2008, 79, 121-127. 
97. Quenelle, D.C.; Prichard, M.N.; Keith, K.A.; Hruby, D.E.; Jordan, R.; Painter, G.R.; Robertson, 
A.; Kern, E.R. Synergistic efficacy of the combination of ST-246 with CMX001 against 
orthopoxviruses. Antimicrob. Agents Chemother. 2007, 51, 4118-4124. 
98. Vora, S.; Damon, I.; Fulginiti, V.; Weber, S.G.; Kahana, M.; Stein, S.L.; Gerber, S.I.; Garcia-
Houchins, S.; Lederman, E.; Hruby, D.; Collins, L.; Scott, D.; Thompson, K.; Barson, J.V.; 
Regnery, R.; Hughes, C.; Daum, R.S.; Li, Y.; Zhao, H.; Smith, S.; Braden, Z.; Karem, K.; Olson, 
V.; Davidson, W.; Trindade, G.; Bolken, T.; Jordan, R.; Tien, D.; Marcinak, J. Severe eczema 
vaccinatum in a household contact of a smallpox vaccinee. Clin. Infect. Dis. 2008, 46, 1555-1561. 
99. Huggins, J.; Goff, A.; Hensley, L.; Mucker, E.; Shamblin, J.; Wlazlowski, C.; Johnson, W.; 
Chapman, J.; Larsen, T.; Twenhafel, N.; Karem, K.; Damon, I.K.; Byrd, C.M.; Bolken, T.C.; 
Jordan, R.; Hruby, D. Nonhuman primates are protected from smallpox virus or monkeypox virus 
challenges by the antiviral drug ST-246. Antimicrob. Agents Chemother. 2009, 53, 2620-2625. 
100. Duraffour, S.; Andrei, G.; Snoeck, R. Tecovirimat, a p37 envelope protein inhibitor for the 
treatment of smallpox infection. IDrugs 2010, 13, 181-191. 
101. Snoeck, R.; Andrei, G.; De Clercq, E. Therapy of poxvirus infections. In: Poxviruses; Mercer, 
A.A., Ed.; Birkhauser Verlag: Basel, Switzerland, 2007; pp. 375-395. 
Viruses 2010, 2                            
 
 
1339 
102. Yang, H.; Kim, S.K.; Kim, M.; Reche, P.A.; Morehead, T.J.; Damon, I.K.; Welsh, R.M.; 
Reinherz, E.L. Antiviral chemotherapy facilitates control of poxvirus infections through inhibition 
of cellular signal transduction. J. Clin. Invest. 2005, 115, 379-387. 
103. Reeves, P.M.; Bommarious, B.; Lebeis, S.; McNulty, S.; Christensen, J.; Swimm, A.; Chahroudi, 
A.; Chavan, R.; Feinberg, M.B.; Veach, D.; Bornmann, W.; Sherman, M.; Kalman, D. (2005) 
Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nat. Med. 2005, 11, 
731-739. 
104. McFadden, G. Gleevec casts a pox on poxviruses. Nat. Med. 2005, 11, 711-712. 
105. Gubser, C.; Smith, G.L. The sequence of camelpox virus shows it is most closely related to 
variola virus, the cause of smallpox. J. Gen. Virol. 2002, 83, 855-872. 
106. Smee, D.F.; Sidwell, R.W.; Kefauver, D.; Bray, M.; Huggins, J.W. Characterization of wild-type 
and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses. 
Antimicrob. Agents Chemother. 2002, 46, 1329-1335. 
107. Duraffour, S.; Snoeck, R.; Krečmerová, M.; van den Oord, J.; de Vos, R.; Holý, A.; Crance, J.-M.; 
Garin, D.; De Clercq, E.; Andrei, G. Activities of several classes of acyclic nucleoside 
phosphonates against camelpox virus replication in different cell culture models. Antimicrob. 
Agents Chemother. 2007, 51, 4410-4419. 
108. Duraffour, S.; Vigne, S.; Vermeire, K.; Garcel, A.; Vanstreels, E.; Daelemans, D.; Yang, G.; 
Jordan, R.; Hruby, D.E.; Crance, J.-M.; Garin, D.; Andrei, G.; Snoeck, R. Specific targeting of the 
F13L protein by ST-246 affects orthopoxvirus production differently. Antivir. Ther. 2008, 13, 
977-990. 
109. Stittelaar, K.J.; Neyts, J.; Naesens, L.; van Amerongen, G.; van Lavieren, R.F.; Holý, A.; De 
Clercq, E.; Niesters, H.G.; Fries, E.; Maas, C.; Mulder, P.G.; van der Zeijst, B.A.; Osterhaus, A.D. 
Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus 
infection. Nature 2006, 439, 745-748. 
 
© 2010 by the authors; licensee MDPI, Basel, Switzerland. This article is an Open Access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 
